Search by Categories
- Insights
- Rare Disease
- Oncology
- Cell and Gene Therapy
- Medical Devices
- Consulting
- News & Analysis
-
Therapeutic Areas
Our expertise in the industry
Albireo Pharma Hopeful to Commercialize its PFIC Treatment by the End of the Year Albireo Pharma, spun out of AstraZeneca, has long been working on developing potential and efficient treatment ...
Amylyx Pharmaceuticals grabs USD 30 Million Amylyx Pharmaceuticals has grabbed USD 30 million boosts after posting positive data, which showed it could help decrease amyotrophic lateral s...
Novo Nordisk has announced to enter into a collaboration with Dicerna’s RNAi platform to focus on metabolic and liver-related diseases. The companies will be focusing to advance the treatment ...
A Praluent boost for Sanofi, and Regeneron The U.S. FDA has given its nod to Praluent (alirocumab) to be used for reducing the risk of heart attack, stroke, and unstable angina requiring hospit...
FDA gives thumbs-up to Balversa The U.S. FDA has granted approval of Balversa (erdafitinib) to Belgium-based Janssen Pharmaceutica, for the treatment of advanced or metastatic bladder cancer. T...
Peloton Therapeutics raises USD 150 Million for treating Advance Kidney Cancer Peloton Therapeutics has been in the process of developing small molecule drugs to treat Cancer, has raised&...
Stopping breast cancer metastasis by killing tumor cells in their sleep Oncology researchers believed that dormant breast cancer cells are not responsive to chemotherapy. But these inactive can...
Axovant tips nelotanserin from small molecule R&D Axovant has stopped nelotanserin development after it missed the primary endpoint in a phase 2 trial in patients with Lewy body dementia. The d...
Novo Nordisk set to restructure R&D business Novo Nordisk, Danish drug maker, declared its plans to reorganise their R&D business, which include lay-off 400 workers of operations in Denmar...
NICE Rejects Gilead Sciences’ Yescarta on Cost Concerns The United Kingdom’s government-funded health service isn’t being so nice to Gilead Sciences’ CAR-T blood cancer treatment Yescar...
With the advent of new-age healthcare industry trends that are evident as of now, there...
Although COVID-19 continued to dominate headlines in 2021, pharmaceutical companies did...
The Biosimilars market is growing at a breakneck pace. The biosimilar market provides a...
Chimeric antigen receptor T-cell (CAR T) therapies are shown to have transformative pot...
There has been limited progress in the approval of novel agents in MDS. It has been a l...
Hear from our subject-matter experts and in-house KOL’s on Pharma and Healthcare market trends.
